LOGIN  |  REGISTER
Chimerix

Healthcare Services Group Reports Q2 2023 Results

July 26, 2023 | Last Trade: US$11.39 0.03 0.26
  • Robust New Business Pipeline Sets Stage For Second Half Of Year Growth

BENSALEM, Pa. / Jul 26, 2023 / Business Wire / Healthcare Services Group, Inc. (NASDAQ:HCSG) reported for the three months ended June 30, 2023 revenue of $418.9 million, GAAP net income of $8.6 million, or $0.12 per basic and diluted common share, and adjusted EBITDA of $26.3 million.

Q2 Results

  • Revenue for the quarter was reported at $418.9 million, with housekeeping & laundry and dining & nutrition segment revenues of $190.8 million and $228.1 million, respectively.
  • Housekeeping & laundry and dining & nutrition segment margins were 8.7% and 5.5%, respectively.
  • Direct cost of services was reported at $367.7 million, or 87.8%. Direct cost included an $11.3 million increase in CECL AR reserves.
  • SG&A was reported at $41.4 million; after adjusting for the $2.3 million increase in deferred compensation, actual SG&A was $39.1 million, or 9.3%.
  • The effective tax rate was 24.6%. The Company expects a 2023 tax rate of 24% to 26%.
  • Cash flow from operations for the quarter was $7.4 million and was impacted by an $18.8 million increase in accrued payroll and a $39.0 million increase in accounts receivable related to the timing of cash collections. DSO for the quarter was 83 days.

Ted Wahl, Chief Executive Officer, stated, “In Q2, we delivered strong core earnings and added to an already robust new business pipeline, while navigating a difficult cash collections environment. Industry fundamentals continue to improve, and a stabilizing labor market and select state-based reimbursement increases have contributed to the gradual but steady occupancy recovery. While there remains uncertainty as to what a minimum staffing requirement might look like for the industry, we remain hopeful that CMS will fully consider the impact on operators before finalizing a rule, and have confidence in our customers’ ability to manage any such rule.”

Mr. Wahl concluded, “We enter the second half of the year with three clear priorities. The first is continuing to manage direct costs at 86%, excluding CECL. The second is collecting what we bill, building on the strong momentum gained in May and June. The third and perhaps the most impactful is the realization of our business development efforts yielding new facility starts. There is a high level of internal enthusiasm as we pivot to growth mode through the back half of 2023 and into 2024.”

Conference Call and Upcoming Events

The Company will host a conference call on Wednesday, July 26, 2023, at 8:30 a.m. Eastern Time to discuss its results for the three months ended June 30, 2023. The call may be accessed via phone at 1 (888) 330-3451, Conference ID: 4431380. The call will be simultaneously webcast under the “Events & Presentations” section of the Investor Relations page on the Company’s website, www.hcsg.com. A replay of the webcast will also be available on the website for one year following the date of the earnings call.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This release and any schedules incorporated by reference into it may contain forward-looking statements within the meaning of federal securities laws, which are not historical facts but rather are based on current expectations, estimates and projections about our business and industry, and our beliefs and assumptions. Words such as “believes,” “anticipates,” “plans,” “expects,” “estimates,” “will,” “goal,” and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Such forward-looking information is also subject to various risks and uncertainties. Such risks and uncertainties include, but are not limited to, risks arising from our providing services to the healthcare industry and primarily providers of long-term care; the impact of and future effects of the COVID-19 pandemic or other potential pandemics; having a significant portion of our consolidated revenues contributed by one customer during the six months ended June 30, 2023; credit and collection risks associated with the healthcare industry; the impact of bank failures; our claims experience related to workers’ compensation and general liability insurance (including any litigation claims, enforcement actions, regulatory actions and investigations arising from personal injury and loss of life related to COVID-19); the effects of changes in, or interpretations of laws and regulations governing the healthcare industry, our workforce and services provided, including state and local regulations pertaining to the taxability of our services and other labor-related matters such as minimum wage increases; the Company's expectations with respect to selling, general, and administrative expense; and the risk factors described in Part I of our Form 10-K for the fiscal year ended December 31, 2022 under “Government Regulation of Customers,” “Service Agreements and Collections,” and “Competition” and under Item 1A. “Risk Factors” in such Form 10-K.

These factors, in addition to delays in payments from customers and/or customers in bankruptcy, have resulted in, and could continue to result in, significant additional bad debts in the near future. Additionally, our operating results would be adversely affected by continued inflation particularly if increases in the costs of labor and labor-related costs, materials, supplies and equipment used in performing services (including the impact of potential tariffs and COVID-19) cannot be passed on to our customers.

In addition, we believe that to improve our financial performance we must continue to obtain service agreements with new customers, retain and provide new services to existing customers, achieve modest price increases on current service agreements with existing customers and/or maintain internal cost reduction strategies at our various operational levels. Furthermore, we believe that our ability to sustain the internal development of managerial personnel is an important factor impacting future operating results and the successful execution of our projected growth strategies. There can be no assurance that we will be successful in that regard.

USE OF NON-GAAP FINANCIAL INFORMATION

To supplement HCSG’s consolidated financial information, which are prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), the Company believes that certain non-GAAP financial measures are useful in evaluating operating performance and comparing such performance to other companies.

The Company is presenting earnings before interest, taxes, depreciation and amortization ("EBITDA"), and excluding items impacting comparability ("Adjusted EBITDA"). We cannot provide a reconciliation of forward-looking EBITDA and Adjusted EBITDA margin measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. The presentation of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for financial statements prepared in accordance with GAAP.

HEALTHCARE SERVICES GROUP, INC.

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(in thousands, except per share data)

     

 

 

For the Three Months Ended

 

For the Six Months Ended

 

 

June 30,

 

June 30,

 

 

2023

 

2022

 

2023

 

2022

Revenues

 

$

418,931

 

$

424,857

 

 

$

836,161

 

$

851,668

 

Operating costs and expenses:

 

 

 

 

 

 

 

 

Costs of services provided

 

 

367,728

 

 

379,370

 

 

 

728,706

 

 

752,632

 

Selling, general and administrative

 

 

41,429

 

 

29,281

 

 

 

81,476

 

 

65,017

 

Income from operations

 

 

9,774

 

 

16,206

 

 

 

25,979

 

 

34,019

 

Other income (expense), net

 

 

1,636

 

 

(7,956

)

 

 

2,987

 

 

(9,988

)

Income before income taxes

 

 

11,410

 

 

8,250

 

 

 

28,966

 

 

24,031

 

 

 

 

 

 

 

 

 

 

Income tax provision

 

 

2,812

 

 

1,430

 

 

 

7,684

 

 

5,882

 

Net income

 

$

8,598

 

$

6,820

 

 

$

21,282

 

$

18,149

 

 

 

 

 

 

 

 

 

 

Basic earnings per common share

 

$

0.12

 

$

0.09

 

 

$

0.29

 

$

0.24

 

 

 

 

 

 

 

 

 

 

Diluted earnings per common share

 

$

0.12

 

$

0.09

 

 

$

0.29

 

$

0.24

 

 

 

 

 

 

 

 

 

 

Basic weighted average number of common shares outstanding

 

 

74,478

 

 

74,337

 

 

 

74,488

 

 

74,332

 

 

 

 

 

 

 

 

 

 

Diluted weighted average number of common shares outstanding

 

 

74,567

 

 

74,358

 

 

 

74,543

 

 

74,345

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HEALTHCARE SERVICES GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands)

    

 

June 30, 2023

 

December 31, 2022

Cash and cash equivalents

$

28,662

 

$

26,279

Marketable securities, at fair value

 

93,185

 

 

95,200

Accounts and notes receivable, net

 

380,061

 

 

336,777

Other current assets

 

47,178

 

 

50,376

Total current assets

 

549,086

 

 

508,632

 

 

 

 

Property and equipment, net

 

26,932

 

 

22,975

Notes receivable — long-term

 

30,740

 

 

32,609

Goodwill

 

75,529

 

 

75,529

Other intangible assets, net

 

13,539

 

 

15,946

Deferred compensation funding

 

37,020

 

 

33,493

Other assets

 

28,912

 

 

29,150

Total assets

$

761,758

 

$

718,334

 

 

 

 

Accrued insurance claims — current

$

24,891

 

$

23,166

Other current liabilities

 

164,773

 

 

155,453

Total current liabilities

 

189,664

 

 

178,619

 

 

 

 

Accrued insurance claims — long-term

 

68,920

 

 

65,541

Deferred compensation liability — long-term

 

37,171

 

 

33,764

Lease liability — long-term

 

11,560

 

 

8,097

Other long term liabilities

 

3,854

 

 

6,141

Stockholders' equity

 

450,589

 

 

426,172

Total liabilities and stockholders' equity

$

761,758

 

$

718,334

HEALTHCARE SERVICES GROUP, INC.

RECONCILIATIONS OF NON-GAAP FINANCIAL MEASURES

(Unaudited)

(in thousands)

     

 

 

For the Three Months
Ended

 

For the Six Months Ended

 

 

June 30,

 

June 30,

 

 

2023

 

2022

 

2023

 

2022

Reconciliation of Net Income to EBITDA and Adjusted EBITDA

 

 

 

 

 

 

 

 

Net income

 

$

8,598

 

$

6,820

 

 

$

21,282

 

$

18,149

 

Income tax provision

 

 

2,812

 

 

1,430

 

 

 

7,684

 

 

5,882

 

Interest, net

 

 

488

 

 

(616

)

 

 

591

 

 

(1,033

)

Depreciation & amortization

 

 

3,595

 

 

3,618

 

 

 

7,315

 

 

7,765

 

EBITDA

 

$

15,493

 

$

11,252

 

 

$

36,872

 

$

30,763

 

Share-based compensation

 

 

2,351

 

 

2,372

 

 

 

4,409

 

 

4,768

 

Gain/loss on deferred compensation, net

 

 

38

 

 

167

 

 

 

82

 

 

456

 

Bad debt expense adjustments(1)

 

 

8,379

 

 

12,398

 

 

 

12,414

 

 

13,506

 

Adjusted EBITDA

 

$

26,261

 

$

26,189

 

 

$

53,777

 

$

49,493

 

(1) The bad debt expense adjustment reflects the difference between GAAP bad debt expense (CECL) and historical write-offs as a percentage of revenues, both of which are based on the same seven year look-back period.

 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB